Delek Group Reports Profit Growth, Plans NIS 250 Million Dividend
Translated & summarized from Globes by baba
Delek Group, controlled by Yitzhak Tshuva, reported a third-quarter net profit of NIS 440 million, a 9% increase year-over-year, and announced a NIS 250 million dividend. Revenues rose 18% to NIS 5 billion, driven by strong performance in its energy subsidiaries Ithaca and NewMed. The company's financial services arm, IsraCard, also saw revenue growth but a decline in net profit. Analyst Lior Vider praised Delek's strategic focus and reduced leverage.
The story in 7 lines · by baba
- Delek Group reported a NIS 440 million net profit in Q3 2026, a 9% increase.
- The company will distribute a dividend of NIS 250 million to shareholders.
- Revenues for Delek Group increased by 18% to NIS 5 billion in the third quarter.
- Energy subsidiary Ithaca saw a 20% increase in average daily production.
- Gas sales from NewMed's Leviathan project rose 16% due to increased exports to Egypt.
- IsraCard's net profit declined, but revenues surpassed NIS 1 billion for the first time.
- Analyst Lior Vider praised Delek's strategy and reduced financial leverage.
Delek Group, controlled by Yitzhak Tshuva and managed by CEO Idan Wells, reported a net profit of NIS 440 million in the third quarter of 2026. This represents a 9% increase compared to the adjusted net profit in the same period last year. The company's revenues across all its business segments rose by 18% to NIS 5 billion. For the first nine months of the year, revenues totaled NIS 14.1 billion, up from NIS 11.6 billion in the prior year.
Following the release of its financial reports, Delek Group announced a dividend distribution of NIS 250 million. The company's stock has seen a modest increase of over 1% year-to-date, with a market capitalization of NIS 15 billion. The profit increase is attributed primarily to improved profitability at Ithaca and NewMed, driven by higher production and energy prices. EBITDAX, a measure of operating profit, surged 62% to $921 million in the quarter and rose 17% to $2.36 billion over the first nine months.
Ithaca, now part of the FTSE 100 index, increased its average daily production by 20% to 117,000 barrels of oil equivalent. NewMed saw a decrease in financial debt, while its gas sales from Leviathan increased by 16% to 3.6 BCM in the quarter, largely due to increased exports to Egypt following the completion of a third pipeline. However, the first nine months' results were impacted by production halts at Leviathan during Operation "Lion's Roar" and a dry well discovery in Bulgaria, which resulted in a NIS 113 million loss for Delek.
In its financial services arm, IsraCard, revenues exceeded NIS 1 billion for the first time in the quarter, with transaction volume up 15% to a record NIS 79.5 billion. However, net profit, excluding one-time expenses, decreased to NIS 55 million from NIS 96 million. IsraCard plans a NIS 300 million rights offering, in which Delek intends to fully participate and potentially increase its stake to 45%.
Delek Group's net financial debt decreased by NIS 160 million to NIS 3.9 billion by the end of September. Analyst Lior Vider commented that the quarterly results demonstrate the success of the group's focused strategy on cash-generating core assets and a significant reduction in leverage. He noted Ithaca's stable cash flow and NewMed's potential in Venezuela, while also highlighting IsraCard's capital strengthening as a wise move.
Mentioned
